Myriad Genetics, Inc’s recently made public that its President and CEO DIAZ PAUL J unloaded Company’s shares for reported $0.34 million on Oct 11 ’24. In the deal valued at $22.93 per share,15,000 shares were sold. As a result of this transaction, DIAZ PAUL J now holds 962,378 shares worth roughly $4.09 million.
Then, DIAZ PAUL J bought 15,000 shares, generating $343,950 in total proceeds.
Before that, Ancona Margaret bought 11,538 shares. Myriad Genetics, Inc shares valued at $321,019 were divested by the Officer at a price of $27.82 per share.
Wolfe Research downgraded its Myriad Genetics, Inc [MYGN] rating to a Peer perform from a an Outperform in a research note published recently. A number of analysts have revised their coverage, including Wells Fargo’s analysts, who decreased its forecast for the stock in early May from “an Overweight” to “an Equal weight”. Guggenheim also remained covering MYGN and has decreased its forecast on April 09, 2025 with a “Neutral” recommendation from previously “Buy” rating. Piper Sandler revised its rating on March 12, 2025. It rated MYGN as “an Overweight” which previously was an “a Neutral”.
Price Performance Review of MYGN
On Monday, Myriad Genetics, Inc [NASDAQ:MYGN] saw its stock jump 9.25% to $4.25. Over the last five days, the stock has lost -44.81%. Myriad Genetics, Inc shares have fallen nearly -69.00% since the year began. Nevertheless, the stocks have fallen -82.25% over the past one year. While a 52-week high of $29.30 was reached on 02/19/25, a 52-week low of $3.86 was recorded on 05/12/25. SMA at 50 days reached $8.38, while 200 days put it at $17.01.
Levels Of Support And Resistance For MYGN Stock
The 24-hour chart illustrates a support level at 3.97, which if violated will result in even more drops to 3.68. On the upside, there is a resistance level at 4.40. A further resistance level may holdings at 4.54. The Relative Strength Index (RSI) on the 14-day chart is 22.67, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -2.39, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 89.66%. Stochastics %K at 4.12% indicates the stock is a buying.
The most recent change occurred on February 12, 2025 when Craig Hallum began covering the stock and recommended ‘”a Buy”‘ rating along with a $29 price target.
